Anagestone Acetate

Summary

Anagestone Acetate (CHEMBL2104489) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 372.5 Da · C24H36O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104489
Name	Anagestone Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	70693507
Molecular formula	C24H36O3
Molecular weight	372.5
InChIKey	KDLNOQQQEBKBQM-HDFGVWRLSA-N

SMILES: C[C@H]1C[C@@H]2[C@H](CC[C@]3(C2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CCCC4)C

IUPAC name: [(6S,8R,9S,10R,13S,17R)-17-acetyl-6,10,13-trimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate

Also known as: Anagestona, Anagestone, Anagestone acetate, Anatropin, NSC-73880, ORF-1658, ANAGESTONE ACETATE

Patent coverage: 35 distinct patent families (49 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).